AIMS: The protease inhibitor indinavir is characterized by an important interindividual pharmacokinetic variability, which results from the actions of the metabolizing enzymes cytochrome P450 (CYP) 3A and the multidrug efflux pump P-glycoprotein (P-gp), encoded by MDR1. Using a population pharmacokinetic approach, we investigated the effect of several MDR1 and CYP3A5 polymorphisms on the pharmacokinetic parameters of indinavir in HIV-infected patients. METHODS: Twenty-eight patients receiving indinavir alone or together with ritonavir were included. Indinavir pharmacokinetics were studied over a 12 h interval. Genetic polymorphisms were assessed by real-time PCR assays and direct sequencing for MDR1 and by PCR-SSCP analysis for CYP3A5. RESULTS: The pharmacokinetics of indinavir were best described by a one-compartment model with first-order absorption. In the final model, the MDR1 C3435T genotype and ritonavir were identified as statistically significant covariates (P </= 0.001) for the absorption rate constant (95% confidence interval on the difference between CC and CT genotype 0.37, 5.53) and for clearance (95% confidence interval on the difference 5.8, 26.2), respectively. Patients with the CYP3A5*3/*3 genotype receiving indinavir alone had a 31% decrease in the indinavir clearance rate compared with patients carrying the CYP3A5*1/*3 genotype. CONCLUSIONS: The MDR1 C3435T genotype affects the absorption constant of indinavir suggesting that P-gp may be implicated in its pharmacokinetic variability. Through its inhibition of CYP3A and P-gp, ritonavir could attenuate the pharmacokinetic variability linked to genetic differences, reducing significantly the interindividual variability of indinavir. However, genotyping MDR1 and/or CYP3A5 to optimize protease inhibitor boosted regimens does not seem clinically relevant.
AIMS: The protease inhibitor indinavir is characterized by an important interindividual pharmacokinetic variability, which results from the actions of the metabolizing enzymes cytochrome P450 (CYP) 3A and the multidrug efflux pump P-glycoprotein (P-gp), encoded by MDR1. Using a population pharmacokinetic approach, we investigated the effect of several MDR1 and CYP3A5 polymorphisms on the pharmacokinetic parameters of indinavir in HIV-infectedpatients. METHODS: Twenty-eight patients receiving indinavir alone or together with ritonavir were included. Indinavir pharmacokinetics were studied over a 12 h interval. Genetic polymorphisms were assessed by real-time PCR assays and direct sequencing for MDR1 and by PCR-SSCP analysis for CYP3A5. RESULTS: The pharmacokinetics of indinavir were best described by a one-compartment model with first-order absorption. In the final model, the MDR1C3435T genotype and ritonavir were identified as statistically significant covariates (P </= 0.001) for the absorption rate constant (95% confidence interval on the difference between CC and CT genotype 0.37, 5.53) and for clearance (95% confidence interval on the difference 5.8, 26.2), respectively. Patients with the CYP3A5*3/*3 genotype receiving indinavir alone had a 31% decrease in the indinavir clearance rate compared with patients carrying the CYP3A5*1/*3 genotype. CONCLUSIONS: The MDR1C3435T genotype affects the absorption constant of indinavir suggesting that P-gp may be implicated in its pharmacokinetic variability. Through its inhibition of CYP3A and P-gp, ritonavir could attenuate the pharmacokinetic variability linked to genetic differences, reducing significantly the interindividual variability of indinavir. However, genotyping MDR1 and/or CYP3A5 to optimize protease inhibitor boosted regimens does not seem clinically relevant.
Authors: P Kuehl; J Zhang; Y Lin; J Lamba; M Assem; J Schuetz; P B Watkins; A Daly; S A Wrighton; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; R Venkataramanan; S Strom; K Thummel; M S Boguski; E Schuetz Journal: Nat Genet Date: 2001-04 Impact factor: 38.330
Authors: I Cascorbi; T Gerloff; A Johne; C Meisel; S Hoffmeyer; M Schwab; E Schaeffeler; M Eichelbaum; U Brinkmann; I Roots Journal: Clin Pharmacol Ther Date: 2001-03 Impact factor: 6.875
Authors: I C van der Sandt; C M Vos; L Nabulsi; M C Blom-Roosemalen; H H Voorwinden; A G de Boer; D D Breimer Journal: AIDS Date: 2001-03-09 Impact factor: 4.177
Authors: M M Malingré; D J Richel; J H Beijnen; H Rosing; F J Koopman; W W Ten Bokkel Huinink; M E Schot; J H Schellens Journal: J Clin Oncol Date: 2001-02-15 Impact factor: 44.544
Authors: M M Ameyaw; F Regateiro; T Li; X Liu; M Tariq; A Mobarek; N Thornton; G O Folayan; J Githang'a; A Indalo; D Ofori-Adjei; D A Price-Evans; H L McLeod Journal: Pharmacogenetics Date: 2001-04
Authors: Natella Y Rakhmanina; Michael N Neely; Ron H N Van Schaik; Heather A Gordish-Dressman; Keetra D Williams; Steven J Soldin; John N van den Anker Journal: Ther Drug Monit Date: 2011-08 Impact factor: 3.681
Authors: Emily J Cox; Neha Maharao; Gabriela Patilea-Vrana; Jashvant D Unadkat; Allan E Rettie; Jeannine S McCune; Mary F Paine Journal: Pharmacol Ther Date: 2019-05-07 Impact factor: 12.310
Authors: Jose R Castillo-Mancilla; Christina L Aquilante; Michael F Wempe; Laura M Smeaton; Cynthia Firnhaber; Alberto M LaRosa; Nagalingeswaran Kumarasamy; Adriana Andrade; Gautam Baheti; Courtney V Fletcher; Thomas B Campbell; David W Haas; Samantha MaWhinney; Peter L Anderson Journal: J Antimicrob Chemother Date: 2016-02-17 Impact factor: 5.790
Authors: Peter L Anderson; Christina L Aquilante; Edward M Gardner; Julie Predhomme; Patrick McDaneld; Lane R Bushman; Jia-Hua Zheng; Michelle Ray; Samantha MaWhinney Journal: J Antimicrob Chemother Date: 2009-08-26 Impact factor: 5.790
Authors: Xinyan Zhang; Camlin Tierney; Mary Albrecht; Lisa M Demeter; Gene Morse; Robin DiFrancesco; Carrie Dykes; Hongyu Jiang; David W Haas Journal: Ther Drug Monit Date: 2013-04 Impact factor: 3.681